15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK1/2 signaling in colon carcinoma cells

Prostaglandins and Other Lipid Mediators

Volumn 73, Issue 1-2, 2004, Pages 111-122

  Yoshinaga, Masahiro ^a   Buchanan, F Gregory ^a   DuBois, Raymond N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

13 S HODE; 13 S hydroxyoctadecadienoic acid; 15 lipoxygenase 1; 15 LOX 1; ERK; Extracellular signal related kinase; NaBT; NDGA; Nordihydroguaiarectic acid; p21 (Cip WAF 1); Peroxisome proliferator activated receptor gamma; PPAR gamma; Sodium butyrate

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE 1; CORIOLIC ACID; LIPOXYGENASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NORDIHYDROGUAIARETIC ACID; PROTEIN P21; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL GROWTH; COLON CARCINOMA; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ARACHIDONATE 15-LIPOXYGENASE; BUTYRATES; CACO-2 CELLS; CARCINOMA; CELL CYCLE PROTEINS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; LEUKOTRIENES; LIPID PEROXIDES; LIPOXYGENASE INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NORDIHYDROGUAIARETIC ACID; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEARIC ACIDS;

EID: 1842610142     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2004.01.001     Document Type: Article

References (32)

1. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta. 1128:1992;117-131.
2. Funk C.D. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta. 1304:1996;65-84.
3. Shappell S.B., Boegin W.E., Olson S.J., Kasper S., Brash A.R. 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am. J. Pathol. 155:1999;235-245.
4. Brash A.R., Boeglin W.E., Chang M.S. Discovery of a second 15S-lipoxygenase in humans. Proc. Natl. Acad. Sci. U.S.A. 94:1997;6148-6152.
5. Baer A.N., Costello P.B., Green F.A. In vivo activation of an w-6 oxygenase in human skin. Biochem. Biophys. Res. Commun. 180:1991;93-104.
6. Daret D., Blin P., Larrue J. Synthesis of hydroxy fatty acids from linoleic acid by human blood platelets. Prostaglandins. 38:1989;203-214.
7. Glasgow W.C., Hui R., Everhart A.L.et al. The linoleic acid metabolite, (13S)-hydroperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylation. Differential response in syrian hamster embryo tumor suppressor phenotypes. J. Biol. Chem. 272:1997;19269-19276.
8. Ikawa H., Kamitani H., Calvo B.F., Foley J.F., Eling T.E. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res. 59:1999;360-366.
9. Shureiqi I., Wojno K.J., Poore J.A.et al. Decreased 13-S- hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 20:1999;1985-1995.
10. Kamitani H., Geller M., Eling T. Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J. Biol. Chem. 273:1998;21569-21577.
11. Waf1/Cip1/Sdi1 association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179:2002;1-14.
12. Yang W., Velcich A., Maridson J. p21 (WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res. 61:2001;6297-6302.
13. Goldberg Y., Nassif II, Pittas A. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells; alterations in tumor suppressor and cell-regulatory proteins. Oncogene. 12:1996;893-901.
14. Huls G., Koornstra J.J., Kleibeuker J.H. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcionomas. Lancet. 362:2003;230-232.
15. Schaeffer H.J., Weber M.J. Mitogen-activated proteinkinases: specific messages from ubiquitous messengers. Mol. Cell Biol. 19:1999;2435-2444.
16. Pages G., Lenormand P., L'allemain G., Chambard J.C., Meloche S., Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8319-8323.
17. His L.C., Wilson L., Nixon J., Eling T. 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J. Biol. Chem. 276:2001;34545-34552.
18. Shiohara M., El Deiry W.S., Wada M.et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
19. McKenzie K.E., Siva A., Maier S., Runnebaum I.B., Seshadri R., Sukumar S. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin. Cancer Res. 3:1997;1669-1673.
20. WAF1 mutation is not a predominant alteration in pediatric bone tumours. Pediatr. Res. 43:1998;393-395.
21. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21 (Cip/WAF 1) CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
22. Jones J.M., Cui X.S., Medina D., Donehower L.A. Heterozygosity of p21 (Cip/WAF 1)WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Diff. 10(4):1999;213-222.
23. Balomenos D., Martin-Caballero J., Garcia M.I.et al. The cell cycle inhibitor p21 (Cip/WAF 1) controls T-cell proliferation and sex-linked lupus development. Nat. Med. 6(2):2000;171-176.
24. Adnane J., Jackson R.J., Nicosia S.V., Cantor A.B., Pledger W.J., Sebti S.M. Loss of p21 (Cip/WAF 1)WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 19(47):2000;5338-5347.
25. Yang W.C., Mathew J., Velcich A.et al. Targeted inactivation of the p21 (WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res. 61(2):2001;565-569.
26. Yue J., Frey R.S., Mulder K.M. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene. 18(11):1999;2033-2037.
27. Tang D., Wu D., Hirao A., Lahti J.M.et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277(15):2002;12710-12717.
28. Hu P.P., Shen X., Huang D., Liu Y., Counter C., Wang X.F. The MEK pathway is required for stimulation of p21 (Cip/WAF 1)(WAF1/CIP1) by transforming growth factor-beta. J. Biol. Chem. 274(50):1999;35381-35387.
29. Sandor V., Senderowicz A., Mertins S.et al. p21 (CIP/WAF 1)-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer. 83(6):2000;817-825.
30. Cho H.N., Lee Y.J., Cho C.K., Lee S.J., Lee Y.S. Downregulation of ERK2 is essential for the inhibition of radiation-induced cell death in HSP25 overexpressed L929 cells. Cell Death Diff. 9(4):2002;448-456.
31. Shureiqi I., Jiang W., Zuo X.et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR gamma to induce apoptosis in colorectal cancer cells. PNAS. 100:2003;9968-9973.
32. Kelavkar U.P., Nixon J.B., Cohen C., Dillehay D., Eling T.E., Badr K.F. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis. 22(11):2001;1765-1773.